Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.5, and our video podcast, CANCER BUZZ TV.

Industry News Archive

FDA Approves Updated Pembrolizumab Indication for UC

On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved a label update to pembrolizumab for first-line advanced urothelial carcinoma (UC). This approval converts the accelerated approval of pembrolizumab to a regular approval.

Read Merck's announcement.

Posted 9/1/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us